Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
Moodys
Johnson and Johnson
McKinsey
McKesson

Last Updated: May 21, 2022

CLINICAL TRIALS PROFILE FOR REGORAFENIB


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Regorafenib

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01002378 ↗ The Effect of Food (High Fat and Low Fat Breakfast) on the Pharmacokinetics of Regorafenib Completed Bayer Phase 1 2009-10-01 An open label, three way crossover study to determine the effect of a high fat breakfast or a low fat breakfast on the pharmacokinetics of a single dose of regorafenib.
NCT01068769 ↗ Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor Completed Bayer Phase 2 2010-02-01 The purpose of this research study is to determine the safety and activity of regorafenib in participants with advanced gastrointestinal stromal tumor (GIST) if the standard approved therapies, imatinib and sunitinib, have failed to control the disease. Regorafenib is a drug that blocks abnormally active signaling enzymes called "tyrosine kinases" which are important to the growth of GIST. This "tyrosine kinase inhibition" is similar to the way that both imatinib and sunitinib work; however, regorafenib blocks certain additional signaling pathways that are not blocked by imatinib or sunitinib. Regorafenib has been not been tested in GIST participants before this research study.
NCT01068769 ↗ Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor Completed Brigham and Women's Hospital Phase 2 2010-02-01 The purpose of this research study is to determine the safety and activity of regorafenib in participants with advanced gastrointestinal stromal tumor (GIST) if the standard approved therapies, imatinib and sunitinib, have failed to control the disease. Regorafenib is a drug that blocks abnormally active signaling enzymes called "tyrosine kinases" which are important to the growth of GIST. This "tyrosine kinase inhibition" is similar to the way that both imatinib and sunitinib work; however, regorafenib blocks certain additional signaling pathways that are not blocked by imatinib or sunitinib. Regorafenib has been not been tested in GIST participants before this research study.
NCT01068769 ↗ Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor Completed Fox Chase Cancer Center Phase 2 2010-02-01 The purpose of this research study is to determine the safety and activity of regorafenib in participants with advanced gastrointestinal stromal tumor (GIST) if the standard approved therapies, imatinib and sunitinib, have failed to control the disease. Regorafenib is a drug that blocks abnormally active signaling enzymes called "tyrosine kinases" which are important to the growth of GIST. This "tyrosine kinase inhibition" is similar to the way that both imatinib and sunitinib work; however, regorafenib blocks certain additional signaling pathways that are not blocked by imatinib or sunitinib. Regorafenib has been not been tested in GIST participants before this research study.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Regorafenib

Condition Name

Condition Name for Regorafenib
Intervention Trials
Metastatic Colorectal Cancer 24
Colorectal Cancer 20
Colorectal Neoplasms 20
Hepatocellular Carcinoma 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Regorafenib
Intervention Trials
Colorectal Neoplasms 91
Carcinoma 29
Carcinoma, Hepatocellular 25
Neoplasms 20
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Regorafenib

Trials by Country

Trials by Country for Regorafenib
Location Trials
United States 622
Italy 107
Japan 86
Germany 75
Australia 69
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Regorafenib
Location Trials
California 44
Florida 33
Texas 30
New York 30
Pennsylvania 29
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Regorafenib

Clinical Trial Phase

Clinical Trial Phase for Regorafenib
Clinical Trial Phase Trials
Phase 4 5
Phase 3 23
Phase 2/Phase 3 2
[disabled in preview] 117
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Regorafenib
Clinical Trial Phase Trials
Recruiting 68
Completed 63
Active, not recruiting 31
[disabled in preview] 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Regorafenib

Sponsor Name

Sponsor Name for Regorafenib
Sponsor Trials
Bayer 83
National Cancer Institute (NCI) 14
Asan Medical Center 9
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Regorafenib
Sponsor Trials
Other 221
Industry 162
NIH 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
AstraZeneca
Harvard Business School
Colorcon
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.